If you’ve wanted the benefits of a GLP-1 but dreaded weekly injections, the Wegovy® pill is now available for chronic weight management.  

Here’s what to know about how the new Wegovy® pill works, how to take it, how it compares to the weekly injection, and what it costs. 

Disclaimer: This article is for educational purposes only and doesn’t replace medical advice from a licensed healthcare provider. Wegovy® is a prescription medication and isn’t right for everyone. Treatment decisions, dosing, and timing should always be made with your care team. 

What is the Wegovy® pill?

The Wegovy® (semaglutide) pill is a once-daily tablet version of Wegovy® that supports chronic weight management in adults, alongside healthy eating and physical activity. It’s the first and only U.S. Food and Drug Administration (FDA)-approved oral GLP-1 for weight management.

It contains the same active ingredient as injectable Wegovy®: semaglutide. The key difference is how it’s taken. The pill is taken once a day, while injections are once a week.

How the Wegovy® pill works in your body

The Wegovy® pill works in the body by acting like GLP-1. This helps long-term weight management when combined with healthy eating and exercise.

The science behind oral semaglutide

Wegovy® contains semaglutide, a GLP-1 receptor agonist. GLP-1 is a peptide hormone your body already makes that helps control appetite and fullness.

Semaglutide helps you feel full sooner, stay full longer after meals, and feel less hungry between meals. Over time, that can make it easier to eat smaller portions and stick with a weight management plan.

Semaglutide does more than help with weight management. Both the Wegovy® pill and injectable Wegovy® have been shown to reduce the risk of serious heart-related problems, such as heart attacks and strokes, in adults who already have heart disease and who are either obese or overweight.

Over time, this heart‑protective effect adds to the benefits people get from weight management with oral semaglutide.

Why the pill needs special technology (SNAC)

A big challenge with any peptide medication (like semaglutide) is that your stomach can break it down before your body absorbs it. Stomach acid and digestive enzymes are designed to break things apart, which is great for food, but not great for certain medications.

That’s why the oral semaglutide pill uses a special absorption helper called SNAC (salcaprozate sodium). SNAC helps semaglutide get through the stomach and into your bloodstream.

Here’s what SNAC does:

• Briefly (for about 30 minutes) protects the semaglutide so the medication has time to be absorbed.
• Changes the stomach environment (including acidity) to help semaglutide stay stable long enough to work.
• Helps the medication pass through the stomach lining, so more of it gets absorbed.

8 key facts about the Wegovy® pill

Here are some important things to know about the Wegovy® pill:

1. It’s FDA-approved for weight management. The FDA approved the Wegovy® pill on December 22, 2025, making it the first oral GLP-1 approved for chronic weight management.
   
   
2. It’s a daily pill, not a weekly shot. You take it once every morning, instead of doing a weekly injection.
   
   
3. Timing matters. You take it with no more than 4 oz of plain water, then wait 30 minutes before eating, drinking anything else, or taking other medications.
   
   
4. Results are similar to the injection. In clinical trials of the pill, people lost about 13.6% of their body weight over 64 weeks. In trials of the once-weekly Wegovy® injection (semaglutide 2.4 mg), people lost about 14.9% of their body weight over 68 weeks.
   
   
5. There are four dose strengths. The Wegovy® pill comes in 1.5 mg, 4 mg, 9 mg, and 25 mg doses. You start at 1.5 mg and sequentially increase over about four months, under the direction of your care team.
   
   
6. It comes at a lower cash price than the shot. The starting cash price is $149 per month for the 1.5 mg dose and increases to $299 per month for the 25mg tablet which is the dose equivalent to the 2.4mg injection priced at $349 per month.
   
   
7. It stores at room temperature. You don’t need to refrigerate the pills, which can make storage and travel easier.
8. Keep it in the original bottle. The Wegovy® pill must stay in its original bottle to protect it from moisture. Don't transfer the pills to a pill case or organizer, as exposure to humidity can affect the medication.

Wegovy® pill vs. Wegovy® injection: Which is right for you?

Whether the daily pill or the once‑weekly injection is right for you depends on your lifestyle, preferences, and comfort with injections. The table below highlights the key practical differences to help you and your care team decide which option might fit you best.

When the pill can be a better fit

The Wegovy® pill often fits people who want to skip injections and don’t mind building a quick morning routine around it. If you already do something consistent each morning, like brushing your teeth and taking a daily vitamin, the pill can slide into that rhythm. 

The tradeoff is the timing: you need that 30-minute window before taking food, drinks (other than water), or other medications. 

Cost can also be a deciding factor. For some people paying cash, the pill has a lower monthly price than the injection, which can make it feel like an easier first step.

When the injection can be a better fit

The Wegovy® injection tends to fit people who want the simplest schedule possible. If you’d rather think about medication once a week, or your mornings are unpredictable, the weekly shot can feel easier to stick with. 

It can also make sense to stay with the injection if you’re already doing well on it and don’t want to change what’s working.

What the research shows for the semaglutide pill vs. injection

Studies suggest both Wegovy® forms can lead to meaningful weight management:

• Wegovy® pill (OASIS 4 study): Average weight loss was about 13.6% at 64 weeks when all participants were included, and around 16.6% among people who stayed on treatment as prescribed.
• Wegovy® injection (STEP trials): About 14.9% to 17.4% average weight loss at 68 weeks across major trials.

Side effects look similar in both forms and are mostly digestive, like nausea, diarrhea, and vomiting.

Check in with your provider if side effects feel impactful and disruptive. You shouldn’t suffer in silence. The knownwell team can work with you to troubleshoot any symptoms that arise. 

Wegovy® has an FDA “black box” warning. Those individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 should not use Wegovy®.

How much does the Wegovy® pill cost?

The cost of the Wegovy® pill depends on whether you’re paying cash or using commercial insurance. Prices can change over time, but the ranges below give a helpful starting point.

For people paying out of pocket, pricing is based on dose:

• 1.5 mg starting dose: $149 per month
• 4 mg dose: $149 per month through April 15, 2026, then $199 per month
• 9 mg and 25 mg maintenance doses: $299 per month

If you have commercial insurance, your cost can be much lower:

• Co-pays can be as low as $25 per month with a savings card, depending on eligibility.
• Coverage varies by plan, so it’s important to check with your insurance provider to understand your benefits.

How the Wegovy® pill compares to injectable Wegovy®

Injectable Wegovy® has a different pricing structure:

• $199 per month for the first two months (0.25 mg and 0.5 mg doses)
• $349 per month after the first two months

For some people, the Wegovy® pill offers a lower starting cash price, while others prefer the weekly injection despite the higher long-term cost.

Who qualifies for the Wegovy® pill?

Adults can qualify for the Wegovy® pill if they meet one of these criteria:

• Obesity: BMI 30 or higher
• Overweight: BMI 27 or higher and at least one weight-related condition, such as high blood pressure, high cholesterol, or type 2 diabetes
• Heart health risk reduction: Adults with heart disease and obesity or overweight, to help lower the risk of major cardiovascular events

Who should not take the Wegovy® pill?

The Wegovy® pill isn’t right for everyone. You should not take it if you have a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

If you have a known allergy to semaglutide or any ingredient in the medication, or if you are currently taking another semaglutide product (like Ozempic or Rybelsus) or another GLP-1 medication, you also shouldn’t take Wegovy® together with that medication. 

That said, you can switch from one GLP-1 medication to another under your clinician's guidance; you just can't take both together.

Important considerations

Keep these key points in mind if you’re considering the Wegovy® pill:

• The Wegovy® pill is not approved for people under 18
• It works particularly well when paired with healthy eating and exercise
• It requires a prescription from a licensed healthcare provider

How to take the Wegovy® pill correctly: Routine and dosing

How to take the Wegovy® pill the right way matters for how well it works. Because it’s absorbed in the stomach, timing and routine are important.

Your daily routine will look like this:

• Sip: Take one pill first thing in the morning with no more than 4 oz of plain water, on an empty stomach.
• Wait: Wait at least 30 minutes before eating, drinking anything else, or taking other medications.
• Swallow whole: Swallow the tablet whole. Don’t crush, cut, chew, or dissolve it.

To help your body adjust and reduce side effects, there’s a specific dosing schedule. The dose increases over time under the supervision of your care team:

• Month 1: 1.5 mg once daily
• Month 2: 4 mg once daily
• Month 3: 9 mg once daily
• Month 4 and beyond: 25 mg once daily (maintenance dose)

If you miss a dose, skip the missed dose and take your next dose at your usual time the following day.

Wegovy® pill side effects: What to expect

The Wegovy® pill comes with some common side effects and more serious ones to be aware of. If you experience any serious side effects, be sure to seek medical attention.

Managing side effects

​​For many people, side effects are mild to moderate and tend to be temporary.

A few steps can help:

• Stay well hydrated. Digestive side effects like nausea or diarrhea can lead to dehydration, and dehydration can make nausea feel worse.
• Talk with your care team about ways to manage nausea, such as adjusting meal timing or food choices.
• Follow the gradual dose increases. Stepping up the oral semaglutide dose slowly (always under provider supervision) helps your body adapt and can reduce side effects over time.

If side effects feel severe or don’t improve, reach out to your care team for guidance.

How the Wegovy® pill is different from Rybelsus

The Wegovy® pill and Rybelsus are the same medication, and both contain oral semaglutide.

Rybelsus has been approved since 2019 to help manage type 2 diabetes, not weight management. The medication isn’t intended for people without type 2 diabetes.

The Wegovy® pill, on the other hand, is FDA-approved specifically for chronic weight management.

There are a few key differences:

Higher doses of oral semaglutide led to more weight loss on average than the 14 mg dose. In one study, a 50 mg daily dose caused about 15% weight loss, which suggests that taking a higher daily dose is linked with greater weight loss overall.

Note: the 50 mg dose has only been used in studies and is not FDA-approved for weight management.

Compounded oral semaglutide: Why it can be risky

Compounded oral semaglutide can be risky because the Wegovy® tablet uses a specific formulation and SNAC technology to help it get absorbed. That SNAC system is a special formulation and isn’t something compounding pharmacies can reliably re-create in the same way.

There are currently no robust clinical data validating compounded oral semaglutide formulations, so any differences in SNAC use or tablet design could lead to exposure that doesn’t match the studied, FDA‑approved product.

Without the right absorption support, oral semaglutide can be absorbed unpredictably. This can affect results, and it can also raise safety concerns if the dose your body absorbs isn’t consistent day to day.

There’s also the bigger issue: compounded medications are not FDA-approved. That means they don’t go through the same review process for safety, effectiveness, and consistent manufacturing. Compounded products can vary in quality, purity, and dosing.

For these reasons, knownwell only prescribes FDA-approved medications to support patient safety.

Ready to take the next step?

If you’re ready to take the next step, the right support can make all the difference. Weight management is more than a prescription. It's about finding what works for your body, your life, and your goals.

At knownwell, we offer:

• Doctors and clinicians with deep experience in obesity medicine and GLP-1 treatment, including oral semaglutide.
• Registered dietitians who work with you on eating patterns that support appetite regulation, digestion, and long-term metabolic health while taking a GLP-1 pill.
• Personalized, ongoing care that includes dose guidance, side-effect troubleshooting, and regular check-ins.
• Judgment-free conversations about body changes, medication preferences, and what progress looks like for you.

Ready to get started? Here’s how it works:

• Virtual visits: Available from home in all 50 states
• In-person clinics: Boston, Chicago, Dallas-Fort Worth, and Atlanta
• Insurance accepted: Most major plans offer coverage

Your care team at knownwell can answer all your questions about the Wegovy® pill. We’ll help you find the right combination of medication, nutrition, and medical support for your body, so you can feel stronger, more energized, and confident in your health journey.

Book a visit with knownwell today and take the first step toward achieving your health goals.

Frequently asked questions 

Is the Wegovy® pill as effective as the injection?

Yes, the Wegovy® pill is as effective as the injection. In clinical trials, people lost about 13.6% of their body weight over 64 weeks.

Both forms use semaglutide and work in the same way. The biggest difference is how often and how you take them, not how well they work.

How long until I see meaningful results on the Wegovy® pill?

It could take up to 12 weeks to see meaningful results. In a study on oral semaglutide for type 2 diabetes (Rybelsus), the dose was gradually increased to 14 mg daily. By the end of the study, people lost about 3% of their starting body weight. 

In a longer study on the Wegovy® pill that increased the dose up to 25 mg daily, people reached an average 13.6% body weight reduction at 64 weeks, compared with 2.2% for those taking a placebo.

Can I switch from injectable Wegovy® to the pill?

Yes, many people on Wegovy® can switch from injectable to pill, but it’s important to do this with guidance from your care team.

Timing, dose transitions, and side effects all matter, and your care team can help make the change safely.

Does insurance cover the Wegovy® pill?

Yes, insurance does cover the Wegovy® pill, but coverage varies by plan. Some commercial insurance plans cover the Wegovy® pill, and co-pays can be as low as $25 per month with a savings card for eligible patients. It’s best to check directly with your insurer to understand your benefits.

What happens if I eat or drink within 30 minutes of taking the pill?

Eating, drinking anything other than water, or taking other medications within 30 minutes of taking the Wegovy® pill can reduce how much of the medication your body absorbs.

This can make the pill less effective. The 30-minute waiting period is important for the medication to work properly.

Can I take other medications with the Wegovy® pill?

Yes, you can take other medications with the Wegovy® pill, but not at the same time. You need to wait at least 30 minutes after taking the Wegovy® pill before taking other medications. If you take multiple morning medications, talk with your care team about the right schedule for you.

Is the Wegovy® pill safe for people with type 2 diabetes?

Yes, the Wegovy® pill is safe for people with type 2 diabetes. The Wegovy® pill contains semaglutide, the same active ingredient as Rybelsus, which has been studied and used in type 2 diabetes at lower daily doses (up to 14 mg).

The Wegovy® pill uses higher doses (9 mg and 25 mg) specifically tested and approved for chronic weight management in adults with obesity or overweight, which is a different indication and dose range than the diabetes studies.

How long do I need to take the Wegovy® pill?

There is no specific timeline for taking the Wegovy® pill, but it’s designed for long-term weight management. Many people continue taking it as long as it’s helping and fits their health goals. Your care team will check in regularly to reassess benefits, side effects, and next steps.

What happens if I stop taking the Wegovy® pill?

When you stop taking the Wegovy® pill, appetite can return to previous levels, and weight regain can happen over time. That’s why ongoing support with nutrition, movement, and medical care plays an important role, whether or not you continue the medication.

‍

Sources list

Andersen, A., Knop, F. K., Vilsbøll, T. (2021). A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs, 81(9), 1003-1030. doi:10.1007/s40265-021-01499-w. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8217049/

Aroda, V. R., Aberle, J., Bardtrum, L., et al. (2022). A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. The Review of Diabetic Studies, 18(2), 1-17. doi:10.1900/RDS.2022.18.78. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9515042/

Bergmann, N. C., Tichenor, M., Rubino, D. (2023). Semaglutide for the treatment of overweight and obesity: A review. Diabetes, Obesity and Metabolism, 25(1), 18–35. doi:10.1111/dom.14863. Retrieved from https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14863

Buckley, S. T., Bækdal, T. A., Vegge, A., et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467), eaar7047. doi:10.1126/scitranslmed.aar7047. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30429357/

Chin, G. C., Potter, A. W., Friedl, K. E. (2024). Body mass index is a barrier to obesity treatment. Frontiers in Endocrinology, 15, 1444568. doi:10.3389/fendo.2024.1444568. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11324493/

Cleto, A. S., Perez, A. I., Aripua, M., et al. (2024). Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: A systematic review and meta-analysis. International Journal of Environmental Research and Public Health, 21(11), 1550. doi:10.3390/ijerph21121550. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39396098/

Fornes, A., Huff, J., Pritchard, R. I., et al. (2022). Once-weekly semaglutide for weight management: A clinical review. Journal of Pharmacy Technology, 38(4), 239-246. doi:10.1177/87551225221092681. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9272494/

Gabe, M. B. N., Breitschaft, A., Knop, F. K., et al. (2024). Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults with obesity: A randomised, double-blind, placebo-controlled, crossover trial. Diabetes, Obesity and Metabolism, 26(12), 5687–5697. doi:10.1111/dom.15802. Retrieved from https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.15802

Gibbons, C., Blundell, J., Tetens Hoff, S., et al. (2021). Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 23(3), 891–901. doi:10.1111/dom.14255. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7839771/

Jensterle, M., Ferjan, S., Janez, A. (2024). The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: A 2-year observational study. Frontiers in Endocrinology, 15, 1366940. doi:10.3389/fendo.2024.1366940. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11043580/

Kane, M. P., Triplitt, C. L., Solis-Herrera, C. D. (2021). Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists. American Journal of Health-System Pharmacy, 78(7), 556-567. doi:10.1093/ajhp/zxaa413. Retrieved from https://academic.oup.com/ajhp/article/78/7/556/6044728

Krajnc, M., Kuhar, N., Koceva, A. (2025). Oral semaglutide for the treatment of obesity: A retrospective real-world study. Frontiers in Endocrinology, 16, 1593334. doi:10.3389/fendo.2025.1593334. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12158668/

Morales, J., Skolnik, N. (2020). Practical guidance for use of oral semaglutide in primary care. Postgraduate Medicine, 132(8), 686-698. doi:10.1080/00325481.2020.1788340. Retrieved from https://www.tandfonline.com/doi/full/10.1080/00325481.2020.1788340

National Academies of Sciences, Engineering, and Medicine. (2024). Behavioral weight loss treatment. National Academies Press. Retrieved on Jan. 15, 2026, from https://www.ncbi.nlm.nih.gov/books/NBK609411/

National Academies of Sciences, Engineering, and Medicine. (2020). Compounded medications. National Academies Press. Retrieved on Jan. 15, 2026, from https://www.ncbi.nlm.nih.gov/books/NBK562888/

Novo Nordisk. (2025). Chronic weight management with Wegovy®. NovoMedLink Healthcare Provider Portal. Retrieved from https://www.novomedlink.com/obesity/products/treatments/Wegovy®/efficacy-safety/chronic-weight-management.html

Novo Nordisk. (2019). FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes. PR Newswire. Retrieved from https://www.prnewswire.com/news-releases/fda-approves-rybelsus-semaglutide-the-first-glp-1-analog-treatment-available-in-a-pill-for-adults-with-type-2-diabetes-300922438.html

Novo Nordisk. (2025). Novo Nordisk's Wegovy®® pill, the first and only oral GLP-1 for weight management in adults, receives FDA approval. Company news release. Retrieved from https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916475

Novo Nordisk. (2025). Wegovy® cost and coverage information. NovoMedLink Healthcare Provider Portal. Retrieved from https://www.novomedlink.com/obesity/products/treatments/Wegovy®/cost-coverage/Wegovy®-patient-savings.html

Novo Nordisk. (2025). What to pay for Wegovy®. Wegovy® Official Website. Retrieved from https://www.Wegovy®.com/obesity/what-to-pay-for-Wegovy®.html

Overgaard, R. V., Navarria, A., Ingwersen, S. H., et al. (2021). Clinical pharmacokinetics of oral semaglutide: Analyses of data from clinical pharmacology trials. Clinical Pharmacokinetics, 60(10), 1335-1348. doi:10.1007/s40262-021-01025-x. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8505367/

Peng, H., Wang, J., Chen, J., et al. (2023). Challenges and opportunities in delivering oral peptides and proteins. Expert Opinion on Drug Delivery, 20(10), 1349-1369. doi:10.1080/17425247.2023.2237408. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10990675/

Reuters. (2025). Novo Nordisk wins US approval for weight-loss pill. Reuters. Retrieved from https://www.reuters.com/sustainability/boards-policy-regulation/novo-nordisk-wins-us-approval-weight-loss-pill-2025-12-22/

Shah, M., Vella, A. (2014). Effects of GLP-1 on appetite and weight. Reviews in Endocrine and Metabolic Disorders, 15(3), 181–187. doi:10.1007/s11154-014-9289-5. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC4119845/

Solis-Herrera, C., Kane, M. P., Triplitt, C. (2024). Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: The oral semaglutide experience. Clinical Diabetes, 42(1), 74–86. doi:10.2337/cd22-0118. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10788673/

Studna, Andy. (2025). FDA Approves Oral Wegovy® Following Positive Phase III OASIS 4 Trial Results. Applied Clinical Trials. Retrieved from https://www.appliedclinicaltrialsonline.com/view/fda-approves-oral-Wegovy®-positive-oasis-trial-results 

Taylor, K., Tripathi, A. (2025). Adult dehydration. StatPearls. Retrieved on Jan. 18, 2026, from https://www.ncbi.nlm.nih.gov/books/NBK555956/

U.S. Food and Drug Administration. (2025). Compounding and the FDA: Questions and answers. Retrieved from https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

U.S. Food and Drug Administration. (2019). RYBELSUS (semaglutide) tablets, for oral use: Prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051Orig1s020,213051Orig1s021lbl.pdf

U.S. Food and Drug Administration. (2025). Wegovy® (semaglutide) tablets, for oral use: Prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf

van Hout, M., Forte, P., Jensen, T. B., et al. (2023). Effect of various dosing schedules on the pharmacokinetics of oral semaglutide: A randomised trial in healthy subjects. Clinical Pharmacokinetics, 62(4), 635-644. doi:10.1007/s40262-023-01223-9. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10023024/

Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine, 393(11), 1077-1087. doi:10.1056/NEJMoa2500969. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2500969

Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. doi:10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2032183